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Extracellular matrix (ECM) proteins collectively represent a class of naturally derived proteinaceous 29 biomaterials purified from harvested organs and tissues with increasing scientific focus and utility in 30 tissue engineering and repair. This interest stems predominantly from the largely unproven concept 31 that processed ECM biomaterials as natural tissue-derived matrices better integrate with host 32 tissue than purely synthetic biomaterials. Nearly every tissue type has been decellularized and 33 processed for re-use as tissue-derived ECM protein implants and scaffolds. To date, however, 34 little consensus exists for defining ECM compositions or sources that best constitute decellularized 35 biomaterials that might better heal, integrate with host tissues and avoid the foreign body response 36 (FBR) . Metrics used to assess ECM performance in biomaterial implants are arbitrary and 37 contextually specific by convention. Few comparisons for in vivo host responses to ECM implants 38 from different sources are published. This review discusses current ECM-derived biomaterials 39 characterization methods including relationships between ECM material compositions from 40 different sources, properties and host tissue response as implants. Relevant preclinical in vivo 41 models are compared along with their associated advantages and limitations, and the current state 42 of various metrics used to define material integration and biocompatibility are discussed. 43
Commonly applied applications of these ECM-derived biomaterials as stand-alone implanted 44 matrices and devices are compared with respect to host tissue responses. 45 46 TOC Graphic: 47 48 Introduction 49
The extracellular matrix (ECM) in various forms and preparations has been pursued as a 50 biomaterial for decades [2] [3] [4] . In general, ECM-based biomaterials represent lipid-free, 51 decellularized protein-based derivatives and purified protein extracts of previously living tissues or 52 organs. This final form differentiates the extracted ECM as a biomaterial compared to its living 53 tissue precursor representing an organ or tissue graft for transplant. The functional and technical 54 justification for using purified ECM as an implant instead of the viable complete tissue or organ 55 form often stems from versatility and flexibility of using the ECM-derived material in many 56 manipulated and inanimate implantable forms incompatible with living cells in full tissues, 57 perceived immune complications of full transplanted tissues or grafted organs, and likely rejection 58 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 implant placement persists seemingly regardless of the material chemistry, implant size or method 83 of introduction. This response remains a daunting challenge for implanted biomaterials. 84 85 As a completely natural material, the ECM has been proposed to be immune-privileged in the 86 sense that, as a natural material, ECM may not succumb to the typical implant fate and series of 87 host reactions to foreign bodies [9] [10] [11] [12] . The logic driving this idea is that naturally derived matrix 88 materials represented by the ECM present naturally derived biomolecular designs and architecture, 89 and biological compositions to interrogating host cells after implantation that attenuate the FBR. 90
By presenting physically and biochemically "native" matrices to implants sites, ECM biomaterials 91 are proposed to rapidly re-establish healing cues and limit foreign body reactions. Nonetheless, 92 despite a significant history of ECM development, analysis and implant use for decades, currently 93 little consensus exists regarding its ultimate capabilities in modulating host reactions. Certainly, 94 host privilege with regards to minimizing the FBR and improving implanted materials performance 95 has not been unequivocally demonstrated. ECM biomaterial utility in implanted forms and its 96 eventual progress in biomedical applications will rely on improved knowledge of compositional 97 identity of decellularized natural materials and how these factors influence host recognition and 98 ultimate implant integration, regeneration and healing. This review examines methods to process 99 tissue explants to yield various ECM materials, assess their composition and then validate their 100 use as biomaterials in preclinical implant models. Understanding the critical performance issues 101 has direct implications on efforts regarding translation of these materials into commercial medical 102 products. 103 104 Increased interest in protein-based implant materials over the past decade [2] [3] [4] has been inspired 105 by both the demand for improved implant materials and tissue transplants and the realization that 106 all synthetic materials elicit a host response that is sustained until the foreign material is removed 107 or degraded. Strategies to modify synthetic implant materials through physical and chemical 108 means have had few noted successes [13] and little effect on long term FBR outcomes [5] . 109
Exploiting the intrinsic ability of ECM to engage with host cells upon implantation is thought to 110 duplicate aspects of wound healing and ameliorate biocompatibility issues. 111 112 M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 6 biomaterial [3] . Further, more complete, discussions on ECM composition, structure and 130 components can be found in the cited resources [24] [25] [26] . 131 132 Collagen represents the simplest and most abundant class of structural ECM protein used as an 133 implant material. It has been studied and applied in purified forms sourced from ECM-rich tissues 134 such as tendon and dermis with interest as an implant material dating back to the early 1960's [27, 135 28] , and citations dating to the 1940's and 1950's relating to experimental collagen implantation 136 [29, 30] . Collagen has a substantial clinical history of use, primarily in an injectable form [31, 32] , 137 and sheet form [33] [34] [35] , and is also reported in many fundamental studies of implants as a coating 138 [36, 37] , chemically modified form [38] [39] [40] , and in diverse solid implant forms [41, 42] Crosslinked Protein Implants and the FBR 151
Resorption and removal of the collagen foreign body leads to an interesting hypothesis that 152 collagen elicits a host response until it is degraded. Evidence supporting this hypothesis can be 153 found through investigation of host responses to cross-linked collagen implants, rendering their 154 degradation and removal more difficult. Analysis of host responses to cross-linked collagen is 155 detailed elsewhere [45] . Numerous studies conclude that prolonged degradation rates from 156 increasing crosslink density are associated with more severe host FBRs as evidenced by the 157 presence of FBGC's, and fibrous capsule formation around the implanted material [39, [45] [46] [47] . The 158 method of crosslinking seems to be largely irrelevant to the FBR intensity achieved. Interestingly, 159 there has been little research into naturally cross-linked collagen host FBRs. While collagen 160 crosslinking via lysyl oxidase, an enzyme responsible for natural collagen crosslinking in vivo, has 161 not been feasible ex vivo, other natural cross-linking methods such as the use of 162 transglutaminases have not been studied with respect to the host FBR [45, [48] [49] [50] . This would 163 substantiate the operative hypothesis that unnatural, therefore difficult-to-breakdown, crosslinking 164 leads to the observed increased FBR to crosslinked collagen implants [45] . 165 166 Natural collagen remodeling is performed through the coordinated enzymatic actions of assorted 167 matrix metalloproteinases (MMPs), with nearly 30 known enzyme members [16] . Combinations of 168 these collagenases/gelatinases are responsible for tissue matrix turnover, regeneration and 169 homeostasis. Non-natural crosslinking using diverse chemical agents (e.g., glutaraldehyde, 170 genipin) likely affects MMP bioactivities against native collagen substrates, producing an 171 imbalance in ECM turnover. Delayed resorption and even substrate inertness to degradation 172 prolongs crosslinked collagen implant presence in tissue, exacerbating host responses to the 173 implant. Non-natural collagen degradation fragments, bearing remnants of added synthetic 174 chemical crosslinkers, are known antigens [51, 52] . 175
176
Beyond Collagen: The Shift to More Complex ECM Implant Materials 177 Despite collagen's ubiquitous and structurally critical presence in all tissues and organs in its 178 different isoforms as an essential structural ECM protein [44, 53, 54] , few studies specifically show 179 seamless integration of collagen implants without foreign body reactions or with the expected 180 "natural" tolerance or biocompatibility. Yet, serious clinical adverse reactions are not commonly 181 reported either. Collagens from autologous or xenogeneic sources are weakly immunogenic in 182 antibody cross-reactivity studies [55] . Clinical observations indicate that only 2-4% of human M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 populations possess inherent immunity (i.e., allergic sensitivity) to bovine collagen [56] . 184
Additionally, animal-sourced collagen extracts may exhibit minor human antigenicity, but 185 traditionally, this sensitivity has been considered generally acceptable for tissue engineered 186 implants for human use [57] . Lastly, published data supporting human immunological benefits of 187 engineered telopeptide-deficient collagens (i.e. free of antigenic epitopes) remains equivocal [58] . 188
Despite substantial medical history, collagen has long operated clinically in a gray zone of implant 189 acceptability with respect to specific host tissue responses. Given the notable lack of prominent, 190 consistent host responses throughout its historical clinical utility, collagen implants have essentially 191 addressed tissue bulking. Further biomedical interest in studying purely collagen implants and host 192 FBR has diminished. Collagen's development as an implant material continues, even after 193 decades of research and translation, but interest in protein-based implant materials has gradually 194 shifted towards decellularized ECM-based extracts, containing collagen as the predominant 195 compositional fraction, but also a much more complex biopolymer composition and architecture. 196 ECM-based scaffolding as a more complex tissue engineered/implantable structure is now 197 attractive. This is perhaps due to specific requirements deemed essential for implant performance, what protocols and standard methods must be used and what biologic components must be 260 monitored and analyzed to assert adequate purity of the resulting matrix. In many cases these 261 criteria will be application-specific, as different tissues gain their unique properties from tissue-262 specific components that comprise them. In general, decellularized tissues should be verified to be 263 techniques can all also be used to determine residual cellular components, and with the exception 273 of mass spectrometry, specific proteins to analyze must be selected and tailored to each assay. 274
This a priori selection of analytes for ECM characterization provides specific, sensitive and detailed 275 information on composition, but is arbitrary and often variable in assay quality, and without content 276 standards. Those ECM components left unmonitored in ECM therefore remain unknown, leading 277 to potential confirmation bias in published results. Additional techniques that are present, but not 278 universally employed, include biomechanical testing [73, 74] this is not an issue, but ECM microstructural or spatial compositional information at high resolution 298
is often critical to inform or detail implant function [3, 77] . Comprehensive ECM structural and 299 compositional information requires application of several different complimentary techniques 300 focused on bulk and location-specific ECM properties. All analytical methods have intrinsic 301 limitations and figures of merit to consider for the value of each assessment to the overall goal. 302
303
Decellularization residuals and trace contaminants 304 305
Innate host cell recognition of ECM components and architecture and resulting functional 306 engagement in vivo makes a decellularized matrix product more attractive over most synthetic 307 biomaterials for implant use and possible tissue regeneration. Therefore, ECM proteins, 308 proteoglycans, glycoproteins, and other biomolecules -collectively responsible both for producing 309 ECM's important microstructure as well as maintaining natural cell interactions --are essential to 310 retain in natural chemical and structural forms in decellularized ECM [26] . Native matricellular 311 polymers such as collagens, elastins, proteoglycans/GAGs, and growth factor contents are 312 commonly assessed. Important trace matrix proteins fibronectin, vitronectin, osteopontin, decorin, 313 biglycan, SPARC, thrombospondin, fibril-associated and network-forming collagens, and many 314 others are less assayed and difficult to quantitate, but are equally important for ECM structure and 315 function [78] . Little discussion is given to other ECM components such as proteinases and 316 proteinase inhibitors, despite their important role in shaping cell actions [79] . Residual ECM 317 proteinases can be regarded as undesirable remnants of decellularization; their residual proteolytic 318 functions after decellularization would degrade desired ECM proteins. It may be more 319 advantageous then for these proteins to be removed from ECM to be restored eventually by 320 incoming newly resident host cells upon implantation. 321
322
As there are many fundamentally important molecules within native tissue that guide cell functions 323 both spatially and temporally, it is currently unknown what specific molecules are essential for neo-324 tissue formation. In response to this ignorance, a large push to more quantitatively describe what 325 remains within a decellularized tissue, represented by both desired and undesired components, is 326
Mass spectrometry techniques 329
Due to its large-scale protein detection capability with a single experiment, mass spectrometry 330 (MS) has become a key analytical method for decellularization characterization [80] . Different MS 331 approaches have been applied to decellularized ECM materials, including LC/MS/MS [71, 72, 81] , 332
ToF-SIMS [70, 82] , and MALDI/ToF [83] . The most common of these techniques is by far the 333 'shotgun' peptide identification approach using LC/MS/MS. Known generally as 'tandem MS', 334 LC/MS/MS relies on heavy pre-analysis techniques to isolate and purify the protein samples for MS 335 [84] . Generally, whole protein samples are first reduced and run on a PAGE gel, often performed 336 on two-dimensional gels, followed by gel extraction and cleanup with liquid chromatography. This 337 is all performed with the intent of reducing sample complexity, remove dominant uninteresting 338 protein background, and enrich the sample in less abundant proteins of interest for identification. 339
Mass spectra are then analyzed and proteins identified using database search programs on 340 derived fragment libraries with user-defined input search parameters. The complex overlap 341 between protein spectra makes for difficult analysis: database searches are not perfect at 342 identifying proteins, and in some cases may falsely identify a protein [85, 86] . 343 344 Time of flight secondary ion mass spectrometry (ToF-SIMS) is an attractive surface analytical 345 method in principle due to its ability to detect proteins on the outer surface of solid or porous ECM 346 implant materials without the extensive preprocessing and solubilization steps required for 347 LC/MS/MS and MALDI/ToF MS. This method will identify species from the outermost 1-2 nm layer 348 of the ECM material. The difficulty in this method, and all MS techniques with proteins, lies in 349 correctly deciphering the complex spectra obtained, correlating up to 10 4 mass peaks to known 350 protein species. Despite multiple attempts, ToF-SIMS has so far been unable to make specific 351 directed assignments to proteins within a decellularized material [70, 82] . This technique is still 352 largely unsuccessful due to the immense overlap of multiple peptides in MS spectra derived from 353 complex decellularized materials composed of hundreds of individual proteins. Continued 354 optimization of spectral analysis may make this a credible ECM analysis technique in the future. 355
Results currently show possibilities to run decellularized ECM MS results against control protein 356 standards to make good approximations of ECM surface composition, particularly if the 357 experimental sample is known to be rich in some specific-signature amino acids [87, 88] . However, 358 since ToF-SIMS does not provide a complete parent ion of a protein, ambiguity in identification 359 remains an issue. Nonetheless, due to its inherent sensitivity, MS will pick out differences when 360 other techniques (e.g., histology or biochemical assays) show that the ECM samples are identical. 361 show that they are indeed compositionally different at their surfaces, and that they then could 364 respond differently to cell infiltrates when implanted. 365 366 Additional contaminants in the ECM sample from decellularization processes could also be 367 confounding factors in MS spectral analysis. Common decellularization buffers include sodium 368 dodecyl sulfate (SDS) and sodium deoxycholate (SDC), of which both could leave remnants 369 without extensive sample washing. These could lead to issues with interpreting positive ion spectra 370 confounded by high amounts of metal (typically sodium) ions preset [89] . In addition to this, other 371 detergents such as Triton and others may also be confusing in MS [90] . While these contaminants 372
should have low abundance with proper decellularization techniques, accurate accounting is 373 required in analysis. MS methods could also serve an important role for the detection of these 374 residual decellularization contaminants in ECM samples. 375 376
Drawbacks of MS Techniques 377
The major drawback of any MS technique is that a protein's presence is inferred based on amino 378 acid fragment analysis, and does so in a way that does not provide precise amounts of protein 379 present, yielding a non-quantitative "yes-or-no" answer, although the field of quantitative 380 proteomics is developing rapidly [91] . The generalized proposal in the literature suggests that a 381 threshold amount of residual cellular material in ECM after decellularization is necessary to invoke 382 a host immune response [81, 92] . MS techniques are not yet able to decipher this threshold level 383 or supply meaningful quantitative data to test this hypothesis and validate threshold levels for 384 purity. So-called "matrix effects" for MS ion extraction efficiencies, overwhelming metal ion MS 385 noise from biological salines, subtle protein isoforms produce further challenges for MS metrics 386
Reviews of ECM decellularization results to date based on MS data have been mixed. In many 389 cases cellular proteins are identified with this technique after decellularization [71, 72] ; however, it 390 has also been used to show that the majority of remnants are related to the ECM [81] . In all cases, 391 large numbers, some greater than 300, of distinct proteins are identified with this method (Figure  392 2). It is unclear, though, if the large variation of reported results with respect to cellular components 393 and numbers of ECM components reported in MS protein data is based on poor sample 394 preparation for analysis or from poor decellularization. Ultimately, with careful analytical validation 395 and standard comparisons, this technique could serve as a valuable tool for identification of 396 important ECM remnant components in tissue replacement/engineered products. 397 398 399 400
Unwanted ECM residual material analysis 401 402
Cellular Nucleic Acids.
Removal of undesired residual cellular material from tissue is 403 predominantly verified by examining remaining DNA and genomic residues [92] . Interestingly, 404 residual ECM RNA is not discussed as a major concern compared to residual DNA, and the 405 prevalence of RNase use in decellularization protocols is comparatively low. It could be that the 406 limited concern is due to the general rapid natural destruction of RNA. Therefore, residual cellular-407 derived DNA has been adopted as a surrogate marker for contaminating cellular materials. 408 Importantly, affirmation of its complete removal is also associated with the important presumption 409 that all other undesired cellular components are also removed including proteins/GAGs, amino 410 acids, and lipids. This assumption is largely unproven and unjustified: nuclear material does not 411 necessarily share the same physicochemical properties as all other intra-and extra-cellular 412 components (e.g., membrane proteins, lipids, enzymes) and would not necessarily interact with 413 decellularization protocols, agents or remaining ECM proteins in the same ways during extractions 414 and purification steps. A seminal recent decellularization review indicates that no studies had yet 415 been performed at that time to understand the effects of ECM-residual DNA towards altering host 416 response or potential for host rejection of that implanted material [4] . However, verification of 417 sufficient cell removal has largely been ascribed in literature to the absence of nucleic acids. In all 418 likelihood, DNA has remained the standout reporter, simply through its ease of quantitation using 419 commercial dye-based optometric assays (e.g., PicoGreen, Invitrogen, and other Hoechst based 420 assays), DAPI/hematoxylin or other histologic staining techniques, and lack of other readily 421 available and acceptable material characterization methods (i.e., without excessive, tedious 422 analysis, inconvenience or expense). At the very least, DNA absence verifies that cell lysis and 423 washing steps were sufficiently rigorous to remove DNA below the detection limits of these DNA 424 assays. However, beyond this, lack of other critical cellular components remains unconfirmed. rejection mechanisms have been widely discussed [107] [108] [109] [110] . The α-gal epitope is much more of a 479 concern when implant sourcing is xenogeneic due to natural antibody production towards α-gal in 480 humans [111] , while MHC could provoke host responses from both xeno-and improperly matched 481 allo-sourced biological materials [112] . These two select proteins, however, represent the few 482 known proteins that must be eliminated from purified ECM intended for implant use. The 483 hypothesis that threshold amounts of these two proteins, as well as all other non-autologous 484 proteins, are required to invoke implant rejection and an adverse host response [81, 92] remains 485 unverified. Clearly defining critical proteins verified to be "low tolerance" contaminants, and their 486 amounts required to induce host responses remains a challenge. Analytical techniques should be 487 standardized and adopted to make such determinations routine, allowing a parsing of ECM 488 preparation methods and resulting products into "safe" and "unsafe" categories for research and 489 clinical translation. 490
491
Asserting tissue-specific ECM identities 492
Throughout the past decade, most tissue types have been decellularized for various reuse 493 applications [3, 113, 114] . The provocative issues underscoring these studies regard 1) how 494 different tissue sources might produce distinct ECM characteristics after complete decellularization, 495
and 2) that these tissue-specific ECM compositional and structural differences are distinct and 496 important to how they recruit host cells in vivo to generate tissue-specific responses. Producing 497 valid and verifiable answers to address these issues has significant user implications for translation 498 as some tissues, (e.g., adipose) are much more readily available than others, such as heart, 499 kidney, lung, liver and brain If "throw-away" tissues, readily harvested like adipose, can be made 500 compositionally representative (through further processing/modification and compositional 501 validation of the resultant material) to other tissue types after decellularization, they would 502 represent a universal ECM source with a verifiable quality standard. This validation would diminish 503 the need to acquire and process difficult-to-source and less abundant organs and tissues for 504 tissue-specific ECM implants and regeneration needs. 505
506
The lack of currently accepted compositional standards in decellularized matrix purification and 507 characterization tools, and the numerous different published decellularization methods used 508 currently [59, 74, [115] [116] [117] [118] showing that decellularization protocols greatly affect the biomolecular compositional remnants, 512 M A N U S C R I P T
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19 particularly with respect to GAG content and thus growth factor content as well. These molecules 513 are more susceptible to detergent treatments and provide the most variability in decellularization 514 outcomes from similar tissues [121] . 515 516 All tissues predominantly comprise analogous base biopolymer materials (collagens, 517 GAGs/proteoglycans, structural proteins elastin and laminin) with the majority of tissues being 518 collagen I by weight. The uniqueness of any tissue is therefore defined by the minor differences in 519 biopolymer composition and structure, and the important different cellular phenotypes organized 520 and orchestrated within it. Most decellularization procedures are deemed successful by comparing 521 the resulting ECM to native tissue using few specific tissue markers. For example, components 522 deemed critical to the identity of cartilage are collagen II and high GAG content [122] while 523 collagens I, IV, laminin, and fibronectin (predominant contributors to the basement membrane) 524 have been deemed critical components to retain in many different tissue types to promote 525 epithelialization (including angiogenesis) [81, 121, [123] [124] [125] . Therefore identifying minimal ECM 526 compositional requirements that functionally distinguish different tissue sources in clinical 527 outcomes for ECM use are likely required to understand exactly what ECM requirements direct 528 tissue-specific host healing properties. While this is the overall goal, functional proof of these tissue 529 specific markers has yet to be shown as a requirement for functional tissue replacement. 530
531
One future approach to explore this issue would be to analyze a decellularized ECM material's 532 inherent ability to stimulate stem cell populations to inhabit, create, and sustain tissue function of 533 any desired type. This is particularly pertinent to tissue-engineered devices where exogenously 534 seeded progenitor cells are promoted to differentiate down specific pathways (often ex vivo) to 535 provide the majority of the neo-tissue function upon implantation. Recruited host cells are sensitive 536 to several other cues secondary to ECM engagement, such as cell-cell contacts, paracrine 537 signaling, growth factor presence, and local mechanics [126] [127] [128] . The role of ECM compositional 538 variation as supplied from different tissues and any significance to ECM-based cellular and tissue 539 endpoints in affecting recruited stem cell phenotypic behaviors, differentiation and eventual cellular 540 functionality in tissue-specific context is largely unknown. To provide mechanistic evidence for this 541 influence, initial efforts will need to report differences in tissue-specific ECM compositions and 542 microstructures with high accuracy to be able to correlate resulting cell phenotypes and ultimately 543 regenerated tissue behaviors in vivo. That these ECM factors could also affect inflammation and 544 chronic host FBR to implants is equally important for clinical use but requires similarly complex 545 studies on controlled ECM materials to provide this information. is the basis for tissue engineering designs that often synthetically place different cell integrin 556 recognition motifs deliberately into biomaterials scaffolds [129] [130] [131] [132] [133] . Several studies provide 557 evidence for decellularized tissue directing stem cell differentiation into tissue proper phenotypes 558 during in vitro culture [61, 121, 123, 134] . Highlighted mechanisms relate to both the mechanical 559 nature of the decellularized product as well as the constituent proteins and molecules retained from 560 decellularization. At some level these two variables are correlated, perhaps inseparable, 561 mechanistically. These studies indicate that mesenchymal stem cell (MSC) or induced pluripotent 562 stem (iPS) cells seeded onto purified heart matrix differentiate into cardiomyocytes [116, 123] . 563
Similarly, MSC seeding into a human decellularized trachea ECM and grown in an air interface 564 bioreactor showed preferential differentiation into the desired cell phenotypes [61] . These 565 examples, though, have other confounding, uncontrolled factors that may also contribute to stem 566 cell fate within ECM. These experiments were performed with both soluble signaling factors as well 567 as tissue-specific decellularized ECM. Nonetheless, cell differentiation was more efficient on 568 decellularized matrix materials regardless of growth factor-conditioned media. This indicates that 569 ECM material composition positively affects seeded cellular outcomes in vitro. 570
571
The possibility that 'cross talk' between the two differing signal sources (physical and soluble) [135] 572 combine to produce this positive feedback system [136, 137] is suggested but largely unverified in 573 ECM. Nonetheless, it seems very likely that addition of soluble signals complements ECM to direct 574 cell-specific phenotypes [138] [139] [140] [141] . Heart-derived decellularized ECM produces the desired cell 575 differentiation to cardiomyocytes, but only circumstantial evidence supports ECM insoluble 576 signaling sufficient to drive cell fate. Interestingly, defining control experiments to validate this idea 577
are not yet been reported. For example, cells not specific to the tissue-specific decellularized ECM 578 material have not been studied to understand how ECM alone dictates cell phenotype. Few reports 579 describe stem cell growth on decellularized ECM where the original ECM source is not the same 580 as the desired targeted tissue type. Mechanistically, only intrinsic ECM-characteristic matrix 581 stiffness and mechanics has been demonstrated to control differentiation [128] , with no known M A N U S C R I P T
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21 experiments yet reporting the mechanism for how tissue-specific ECM might guide differentiation to 583 tissue-specific resident cell phenotypes required for regenerative medicine. 584 585 Critical roles of ECM microstructure and composition are evident in a recent study that cultured 586 fibroblasts on both decellularized diseased (i.e., idiopathic pulmonary fibrosis) and healthy lung 587 tissue. Fibroblasts were similarly sourced from both healthy and diseased tissues. It was found 588 that ECM source, instead of cell source, had the greater effect on resulting cell phenotype, with 589 diseased ECM driving fibroblast gene expression towards the diseased state [142] . 590
591
In vivo assessment of ECM implant biocompatibility 592
Material biocompatibility is the composite result of a complex series of biological/immunological 593 events and the host physiological context in which the material is placed [143] . Hence, 594 biocompatibility cannot be accurately assessed in vitro where full competence of either the host 595 biology or physiology is lacking. Despite FDA recommendations for extensive ISO10993 in vitro 596 assays as a biocompatibility assessment, comprehensive assessment of both of these 597 biocompatibility criteria mandates use of in vivo test systems [144, 145] . Importantly, even the 598 relevance of in vivo models for biomaterial implant assessment is questioned since commonly used 599 rodent physiological and immunological systems are distinct from humans in many respects [146-600 148] . Choice of animal species used, in vivo site of placement (e.g., subdermal, intramuscular, 601 percutaneous, transcortical), time point to explantation, and metrics used to assess host tissue 602 responses are variable and lack standardizations for reporting. Hence, common animal implant 603 models for host material response analysis, linking common host responses across various 604 species, and variations in response varying by implant anatomical location are now discussed. 605 Surprisingly, little consensus or consistency is found in published literature for host-implant 606 integration metrics for implant healing versus FBR. Comparisons of ECM implant capsular 607 thickness, neovascularization, giant cell formation, leukocyte infiltrates, select cellular inflammatory 608 markers (e.g., chemokines, cytokines) with standardized endotoxin-controlled implants in 609 standardized surgical procedures, sites and accepted animal models would be useful for 610 comparative ranking and assessments.
These in vivo implant metrics for ECM biomaterials 611 require an understanding of the relative benefits and deficiencies of current implant models used 612 routinely for assessing host response. 613
Recognized differences between rodent species in wound healing research relevant to the FBR M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

22
Rodent species (syngeneic mice and rats) remain the most common animals used to probe 615 biomaterial-host responses [149] . Their utility lies with their ease of use related to relative cost, 616 housing, adaptable surgical procedures, handling and throughput. Availability of genetic mutants, 617 knock-ins, and knock-outs in the mouse and the relative abundance of murine-specific molecular 618 probes for histology, biological assays, and PCR are both substantial benefits as well. Rodents 619 also lie near the boundary of the lowest mammalian species required to provide a representative 620 host tissue response to humans [150] . The guinea pig is another rodent used, although more 621 rarely, as an animal model in FBR research. By contrast, large animal models are much more 622 rarely compared to mice and rats due to logistic/ethical/cost concerns as well as lack of molecular 623 probes for histology and profiling. However, large animals remain useful, and often required due to 624 closer physiologic overlap with humans than rodents, for late stage/pre-clinical experimentation 625 [149] . 626
Differences in rodent tissue physiology and immune responses compared to humans, and even 627 within the different rodent species, must be explained and justified for any model. Several studies 628
show differences in the reported host tissue responses to subdermal collagen and synthetic 629 fluoropolymer (ePTFE) implant materials between mice and rats [151] [152] [153] . These studies were 630 primarily focused on differing immune systems and implant activation of immune cells [152] and 631 cytokine/chemokine signaling differences [153] . These studies compared different material 632 chemistries (ePTFE and dermal collagen, respectively), noting increased inflammatory cells 633 (macrophages) and inflammatory signaling in rats compared to mice. Not only was the final 634 outcome noted to be different, but cellular and inflammatory signaling dynamics were shown to 635 differ as well. Results such as these serve as examples of nuanced differences between rodent 636 species that may lead to altered interpretations of host FBR development when biomaterial and 637 implant location are controlled. Ultimately, these seemingly subtle differences have the potential to 638 lead to translational issues as ECM materials are scaled up towards clinical testing. Additionally, 639 the mere presence of these differences in host response could be indicative of further unknown 640 differences yet to be investigated. 641
Differences in host response to implant location 642
A similar yet distinct collagen implant study comparing host tissue response development between 643 differing implant locations in a common animal model showed that host immune response 644 mechanisms vary within the same animal [16] . This study compared collagen discs implanted at 645 two different locations in a mouse model: supra-epicardially and subcutaneously. Differing 646 inflammatory cytokine signaling was noted between these two locations along with a change in M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 23 MMP activity, leading to differing collagen implant degradation rates with a stronger FBR 648 developed in the epicardial region. The observed collagen disc FBR was assessed based on 649 higher influx of inflammatory cells, including macrophages and polymorphonuclear (PMN) cells, 650 increased angiogenesis, and increased inflammatory signaling profiles in the superepicardial 651 region. These two examples emphasize that appropriate expert attention be directed to selecting 652 an animal model for host response assessments to implants. Additionally, should this prove 653 representative of the human scenario, these results may also offer insight into whether eventual 654 clinical device utilization may be implant location-dependent for performance outcomes. 655
Mouse models seeking mechanisms to in implant-related wound healing and the FBR 656
Several mouse models have been reported for elucidation of more detailed mechanisms of the 657 host response to implanted biomaterials. These include both genetically altered, or knock-out-658 based, and surgical models. Prominent murine knock-out systems have been used to determine 659 the importance of certain matrix metalloproteinases and their control by thrombospondins 1 and 2 660
[154] in host-implant FBR development. Similar matricellular proteins --SPARC, tenascin-C, and 661 osteopontin --have also been implicated in FBR development through similar knock-out mouse 662 models [155] . These proteins are now implicated in roles related to increased angiogenesis and 663 development of a fibrous capsule. Other knock-out models have demonstrated the importance of 664 fibronectin in mounting a strong host tissue response to implants [156] and the presence of 665
FBGCs, despite lack of IL-4, in a T-cell deficient mouse model [157] . Other knock-out mice models 666 have been applied to ECM-based implant materials as well, predominantly studying the effects of 667 cytokines and signaling molecules implicated in host FBR development [151, 158, 159 ]. An 668 interferon-γ (i.e., a macrophage-activating cytokine) knock-out model was used to identify its 669 relationship to host rodent FBR mechanisms to dermal sheep collagen implants, and showed that 670 interferon-γ had little effect on host response outcomes in mice, with similar presence of 671 macrophages and FBGCs [151] . These unique mouse models serve as precision tools to analyze 672 specific molecular or cellular contributions to implant-centered healing and FBR development. 673 Furthermore, they may prove beneficial in probing individual influences of biochemical and 674 biomechanical effects on decellularized ECM integration and host response developments. While 675 their use in FBR studies has spanned more than a decade, wide adoption has yet to be seen and 676 consensus on their general utility in this context is not established. 677
Common surgical implant models to study the FBR include the subcutaneous pouch (either 678 through blunt dissection or minimally invasive needle injection) [8, 13, 19, 22, 160, 161] , abdominal 679 wall defect [162, 163] , intraperitoneal space [154, 164, 165] and dorsal skinfold chamber [166] [167] [168] M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 24 models. Previously, the cage implant system was a popular method for studying implant/host tissue 681 responses [169] [170] [171] . This model has seen less use recently compared to heavy use 20-30 years 682 ago, due possibly to recognized limitations in delineating the host response to the implanted cage 683 material itself versus the test materials within the subdermal cage. As discussed above, differing 684 implant locations may provoke differing FBR responses, making direct comparisons between 685 anatomical implant locations difficult without careful controls. Other less common models are 686 typically contextually based on specific disease states such as surgical removal of muscle or the 687 abdominal wall as a mimic of hernia [172] , replacement of the aorta for testing synthetic vascular 688 grafts [173], brain implantation of neuronal stimulating electrodes [174] and hard tissue implants in 689 bony defects either with or without fixation tools to stabilize the implant site [175] . 690
Collectively, rodent implant studies highlight the prominent mechanistic differences occurring within 691 similar species, and that the FBR for implants develops ubiquitously as a complex process 692 dependent on several requisite but independent physiological cues. To dissect this complex 693 parameter set affecting ECM-based implants, further insight must be gained as improved models, 694 particularly using CRISPR-based genomic modifications [176] [177] [178] , knock-out/in, and new gene 695 reporter (i.e., fluorescent protein) systems are developed and utilized in FBR assessments to 696 various ECM to distinguish key determinants for host tolerance and regenerative medicine. Host 697 response variability depending on host species physiology and immune competence, wound 698 healing dynamics and mechanisms, tissue site, genetic strain, and types of implantation methods 699 are all potentially confounding factors influencing FBR results that may be improved using these 700 new techniques. Host responses are a complex set of dynamic tissue site reactions to material 701 presentation: both sides contribute to the resulting balance of observed FBR responses. Given the 702 plethora of variables in these models, concluding that the in vivo response observed is solely 703 implant material-dependent (or biomaterial-controlled) is rarely unequivocally shown. Importantly, 704 ECM-based implants to date show few clinically important differences to any other implant material 705 class: their utility and possible advantages need to be vetted in the proper (currently unidentified) in 706 vivo FBR models, of which no rationale currently exists for any particular animal model over 707
another with regards to reliable predictability of general FBR outcomes. 708
Cell phenotypic differences between implant responses in rodents versus humans 709
The utility of any animal model in translation is only verified if it actually serves as an accurate and 710 predictive representation of the analogous human scenario. In this context, to correlate host FBR 711 mechanisms to ECM implants to those gleaned from non-standardized rodents, differences 712 between rodents and humans relevant to their healing transition from acute to chronic inflammatory to other disease states such as cancer [179] . Fortunately, evidence indicates that the monocyte-716 macrophage system is relatively conserved between wild type mice and human (though not 717 necessarily in specialized murine models compatible with biologically derived humanized implants, 718 e.g. NOD/SCID mice) [180] . The dynamic mobilization process of monocyte extravasation from 719 bone marrow to the circulatory system and recruitment response to tissue inflammation tends to 720 follow the same differentiation pathways. Given the macrophage's central role in developing and 721 sustaining the FBR [5, 15, 181] , murine macrophages are likely to respond in a contextually 722 accurate manner in mice, representative of the human scenario. Mast cells, more recently 723 emphasized as a dominant early cell type directing the host FBR [5, [182] [183] [184] , show marked 724 differences between murine and human systems [185] . Most significantly, mast cell numbers are 725 much lower in the mouse --only 10-20% of that seen in humans. Additionally, mast cells have 726 been shown to populate the peritoneal space in mice, but are not seen in human peritoneum. 727
These differences, while not functionally conclusive, highlight the potential for altered immune cell 728 responses to implanted materials between these two species. New developments of humanized 729 mouse models, also given noted deficiencies, could pave the way for more representative 730 preclinical testing for material compatibility which to date have focused more on intra-cellular 731 dynamics, instead of the larger scale material/host interactions [186] . 732
Comparisons between rodent and human host responses to ECM materials 733
Decellularized ECM-derived implants in humans: explanted analyses. Several clinically used 734 implant materials are derived from decellularized tissues [see Table 3 ]. These biomaterials vary 735 across their sourced species of ECM origin, physical and chemical forms, and intended uses, each 736 applying proprietary decellularization methods. Their ECM clinical use in humans and preclinical 737 testing in laboratory animals facilitates some comparisons of host responses to these particular 738 ECM materials between species where reported. However, comparisons between preclinical 739 research animal data and human clinical use is difficult due to the lack of direct side-by-side 740 comparison studies using the same metrics for determining their representative host FBR's. The 741 general clinical expectation is that a device is safe and provides better results than what may be 742 achieved with either no, or other, treatment. This focus does not necessarily include screening for 743 common FBR/tissue integration results (Table 1) . 744
In general, the decellularized implant products shown in Table 3 tend to perform well with few 745 reported issues with their use in diverse implant sites (typically soft tissue), particularly in humans M A N U S C R I P T [35, 187, 188] . A number of clinically approved matrix protein-derived devices see regular use in 747 patients in numerous locations in vivo, primarily as tissue fillers/bulking agents (see Table 3 ) with 748 safe outcomes. There are, however, reports indicating negative clinical results with some products. 749
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It has been shown that porcine small intestinal submucosa (SIS -see Table 3 ), at least in an 8-ply 750 configuration, is associated with post-procedural complications in vaginal wall repair, with up to 751 60% of patients in one study showing intense inflammation through 39 days after implantation 752 [189] . Associated complications included lack of tissue repopulation and blood vessel infiltration, 753 with high levels of fibrosis in the periphery of the implanted material. However, no immune 754 screening was performed on these patients and biopsies were not examined for typical signs of a 755 foreign body response such as presence of FBGCs. Porcine SIS used in other surgical sites did 756 not necessarily follow this particular intense inflammatory trend. The use of Surgisis™ in hernia 757 repair shows safe and satisfactory results out to five years [190] , with some evidence of dense 758 fibrous connective tissue and a slight FBGC response in the repaired abdominal wall at 5 years, 759
Other reports in human clinical use also report positive outcomes using Surgisis™ material for 760 hernia repair often indicating better results than repair with synthetic mesh alternatives, although 761 specific host response metrics were not examined in these studies [162, 191] . The general trend 762 for this material's use in hernia repair was some general post-procedural inflammation with a slight 763 FBGC response. 764
Unfortunately, these human results are not fully consistent with preclinical rodent models of hernia 765 repair with this same decellularized ECM implant material. Studies performed in rats are mixed 766 overall representing both positive and negative outcomes related to FBR development and implant 767 biocompatibility concerns [192] [193] [194] . Results of these animal studies all represent more severe 768 outcomes than what is implied by human clinical reports to date. However, there is a range for how 769 far the rodent implant response to ECM seems to deviate from the human scenario. Based on 770 these reports, the predictive accuracy of preclinical rodent testing, at least for decellularized 771 materials intended to aid in hernia repair, is questionable at best. Further discrepancy is shown in 772 porcine SIS implant studies performed in mice, exhibiting no abnormal inflammation or pathology in 773 both abdominal wall defect and subcutaneous pocket models, and with a noted lack of FBGC 774 formation and increase in macrophage numbers [195, 196] . This indicates a potential difference, 775 then, between mouse, rat, and human responses to porcine mucosa-sourced ECM implants. (Table 3) . Simply stated, a lack of consensus between rodent 778 studies and clinical outcomes predominates. Confounding this scenario is a general lack of 779 reported literature results that directly compare the two host scenarios for common human vs. repair, the question becomes whether the same host response is actually seen, but has no effect 782 on patient well-being, or whether there truly is a less severe host FBR observed in human use 783 versus animal models. Beyond the example of SIS for hernia repair, that this finding consistently 784 represents the general case for SIS in all implant locations remains unproven. Such a retrospective 785 analysis of results to date and their reporting is challenging but needed. 786
Porcine SIS has been studied for over 20 years, yet there remains no direct consensus on the 787 detailed biocompatiblity outcomes and how host response varies across mammalian species. 788
Currently, SIS is regarded as safe to use and is thought to be a better mesh implant than similar 789 synthetic polymeric materials [197] . The extensive history and ongoing work with this ECM-based 790 biomaterial should serve as the standard for benchmarking future decellularized biomaterial 791 development, informing the biomaterials community as to how to accurately assess preclinical and 792 clinical outcomes and evaluate successes and failures in translation. Importantly, different tissue 793 processing techniques from the same source (i.e., porcine SIS) show markedly different results 794 [198] , further complicating the selection and de-risking of new efficacious ECM-based materials, 795 and highlighting the need for detailed material characterization post-decellularization/processing. 796
As more tissues are decellularized and developed as possible clinical products, SIS history should 797 be carefully examined to not repeat the same mistakes, and to emulate relative SIS success with 798 other future ECM-derived implant materials. 799 Matrix protein-based biomaterials and ECM implants have a long track record of investigation, 802 some with clinical translation. Yet, despite substantial clinical experience, basic mechanisms of 803 biomaterial integration with human tissues, and rejection responses in some cases, remain 804 unexplained and poorly dissected. In many respects, researchers still pursue questions posed 805 nearly a half century ago as to how to craft human proteins into functional, compatible biomaterials. 806
Decellularization of tissues and organs to produce tissue-specific ECM represents the latest 807 chapter in this protein-based biomaterials saga, facing primarily the same issues and questions, 808 and with similarly few answers. Host response mechanisms are not well understood, and design 809 principles for guiding ECM processing, purity, composition, and microstructure are not evident or 810
benchmarked. 811
Nearly all major organs and tissue have been decellularized for use as scaffolding biomaterials, 812 both for in vitro cell growth or implantation as complex biomaterials, primarily to guide wound 813 healing and tissue regeneration. Some ECM clinical translation has occurred, but this has occurred 814 slowly, at substantial cost, commercial risk, and without much momentum as difficulties remain in and what potential contaminants must be eliminated. Even those obvious contaminants that must 817 be eliminated (e.g., endotoxins, nucleic acids, extraction aids) have few validated ECM-relevant 818 assays to monitor them. What else that remains as trace contaminants or that constitutes ECM 819 compositional and structural heterogeneity and that might therefore define ECM purity and 820 performance in vivo remains unknown. The current non-standard, unvalidated and arbitrary 821 collection of tissue decellularization protocols has little guidance or enforcement from recognized 822 expert bodies such as ASTM, FDA, or ISO organizations. Identification and standard execution of 823 best-practices decellularization protocols are best obtained through consensus via endorsed, 824 rigorously applied, proven and then standardized methods. 825 Sufficient evidence exists that decellularized and other protein-and ECM-based biomaterials can 826 have interesting research-focused and impacting clinical applications and contains the requisite 827 properties to regenerate into functional tissue. Increasing amounts of human-relevant data can 828 serve as precedent to establishing new decellularized biomaterials technologies. However, a full, 829 scientifically mature understanding of how decellularized ECM biomaterials specifically engage 830 host tissues, and how host tissue reacts to ECM implants, compositions and forms in diverse 831 context is required. Comprehensive analytical validations of matrix purity, standardization of 832 methods of extraction and purification, and vetting in proper preclinical models using accepted 833 methods are compelling. Without such protocols and evidence, currently required for all synthetic 834 biomaterial implants, protein-and ECM-based biomaterials development will remain inconsistent 835 and empirically based without rational scientific explanations for its implant performance. 836
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